Sedation
Conditions
Keywords
To see if sedation with dexmedetomidine results in faster emergence after end of intensive care treatment in children, treatment
Brief summary
Dexmedetomidine will be tested against midazolam in a prospective, randomized, double-blind study of intensive care children, age 2-17 years. The investigators' primary hypothesis is that time from end of medication to extubation will be shorter with dexmedetomidine sedation.
Interventions
DRUGdexmedetomidine
Dexemedethomidine is given as major sedative drug
DRUGMidazolam
Midazolam is given as major sedative drug
Sponsors
Ullevaal University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
2 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* informed consent from parents * age between 2 and 18 years * anticipated need of respirator treatment for more than 24 hrs * included in study within 48 hrs of admission to intensive care unit (ICU)
Exclusion criteria
* severe, unstable circulatory failure * severe intracranial or spinal trauma with circulatory instability * sever bradycardia or atrioventricular (A-V) block * liver failure * less than 50% chance of anticipated survival * known allergy to study drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time from end of sedation to extubation | 1-24 hrs |
Countries
Norway
Outcome results
None listed